Movatterモバイル変換


[0]ホーム

URL:


TME Pharma

TME Pharma

TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME.TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned. 

Updated corporate presentation with ESMO 15 Sept 2024 Oral Presentation data showing statistically significant improvement in survival
of NOX-A12 + anti-VEGF + Radiotherapy

Press Release


2025, March 28
06:00 p.m.

TME Pharma provides results of fifth exercise of Warrants Z

2025, March 13
06:00 p.m.

TME Pharma announces filing of patents for use of CCL2 inhibitor NOX-E36 in ophthalmology and presentation at ARVO 2025 of preclinical data showing benefit in glaucoma filtration surgery

2025, February 17
08:00 a.m.

TME Pharma CEO message 2025

Events

NEAUX CANCER 4th ANNUAL CAGLA CONFERENCE

Aram Mangasarian
March 27 – 29 | New Orleans, USA

Latest Analyst Report

Invest Securities
Jamila El Bougrini, PhD
2025, February 07 (EN/FR)

We use cookies

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (Google Analytics cookies). You can decide for yourself whether you want to accept the cookies. Please note that if you refuse cookies, you may no longer be able to use all of the site's functions.

I accept cookies and analyticsDecline
More information |Imprint

[8]ページ先頭

©2009-2025 Movatter.jp